Análise clínica e terapêutica dos pacientes oncológicos atendidos no programa de dor e cuidados paliativos do Hospital Universitário Clementino Fraga Filho no ano de 2003

Giselane Lacerda Figueredo Salamonde; Nubia Verçosa; Louis Barrucand; Antônio Filpi Coimbra da Costa

doi:10.1590/S0034-70942006000600005

Scientific Article

Análise clínica e terapêutica dos pacientes oncológicos atendidos no programa de dor e cuidados paliativos do Hospital Universitário Clementino Fraga Filho no ano de 2003

Clinical and therapeutic analysis of oncology patients treated at the pain and palliative care program of the Hospital Universitário Clementino Fraga Filho in 2003

Giselane Lacerda Figueredo Salamonde; Nubia Verçosa; Louis Barrucand; Antônio Filpi Coimbra da Costa

http://dx.doi.org/10.1590/S0034-70942006000600005 Braz J Anesthesiol, vol.56, n6, p.602-618, 2006

PDF

Downloads: 0

Resumo

JUSTIFICATIVA E OBJETIVOS: Os cuidados paliativos têm como meta principal o controle da dor e de outros sintomas nos pacientes com doenças crônicas, sem possibilidade de cura, sobretudo no câncer avançado. A dor intensa acomete 75% dos pacientes com câncer avançado, interferindo na qualidade de vida e segundo a OMS é considerada uma emergência médica mundial. Este estudo avaliou o perfil dos pacientes oncológicos do Programa de Tratamento da Dor Crônica e Cuidados Paliativos do HUCFF/FM/UFRJ, ressaltando a atuação do anestesiologista, as medicações utilizadas, a humanização do tratamento e a melhor qualidade de vida do paciente. MÉTODO: Retrospectivamente, foram analisados os prontuários dos pacientes oncológicos no ano de 2003. Destacaram-se os parâmetros: idade, raça, sexo, doenças preexistentes, órgão de origem do câncer, tipo de dor e outros sintomas, medicações utilizadas, rotinas hospitalares e o término do tratamento. RESULTADOS: Os tipos de dor encontrados foram nociceptiva, neuropática e incidental, avaliadas utilizando-se a escala unidimensional de faces. Verificou-se a analgesia controlada pelo paciente (PCA) com metadona, via oral, em ambiente domiciliar na 1ª semana. Após esse período, o paciente retornava ao ambulatório para o cálculo da dose regular da metadona. Outros opióides utilizados foram codeína, tramadol, morfina e oxicodona. Além da dor, os pacientes apresentaram: constipação, náuseas, vômitos, delirium, alteração do sono e dispnéia. Os neurolépticos, corticóides e laxantes foram usados como fármacos adjuvantes. CONCLUSÕES: A analgesia controlada pelo paciente utilizando a metadona mostrou-se segura e eficaz pela não-ocorrência de efeitos colaterais significativos. O conhecimento clínico e farmacológico do anestesiologista na equipe multiprofissional proporcionou melhor atendimento para o alívio dos sintomas dos pacientes e humanização no período final de vida.

Palavras-chave

ANALGÉSICOS, Opióides, CUIDADOS PALIATIVOS, DOR, Oncológica, DOR, Oncológica

Abstract

BACKGROUND AND METHODS: The main goal of palliative care is the control of pain and other symptoms in patients with chronic diseases without possibility of cure, especially advanced cancer. About 75% of patients with advanced cancer experience severe pain, which interferes with quality of life and, according to the WHO, it is considered a worldwide medical emergency. This study evaluated the profile of oncology patients enrolled in the Chronic Pain Treatment and Palliative Care Program of the HUCFF/FM/UFRJ, focusing on the role of the anesthesiologist, medications used, humanization of the treatment, and improvement in patient's quality of life. METHODS: The 2003-oncology patients' charts were analyzed retrospectively. Several parameters were compared: age, race, gender, preexisting conditions organ the cancer originated from, type of pain and other symptoms, medications, hospital routine, and end of treatment. RESULTS: The types of pain included nociceptive, neuropathic, and incidental, which were evaluated using the unidimensional faces pain rating scale. In the first week, patients were treated with home-based patient controlled analgesia (PCA) with oral methadone. After this period, the patient returned to the clinic to calculate the regular dose of methadone. Other opioids used included codeine, tramadol, morphine, and oxycodone. Besides pain, patients experienced: constipation, vomiting, delirium, sleep disturbances, and dyspnea. Neuroleptics, corticosteroids, and laxatives were also used as adjuvant therapy. CONCLUSIONS: Patient controlled analgesia with methadone is safe and effective, since there were no significant side effects. The clinical and pharmacological knowledge of the anesthesiologist in the multidisciplinary team provided for better patient care, relief of symptoms, and humanization of the final stages of life.

Keywords

ANALGESICS, Opioids, PALLIATIVE CARE, PAIN, Oncologic, PAIN, Oncologic

References

Magno JB. Hospice care: an overview. Henry Ford Hosp Med J. 1991;39:72-73.

Melo AGC, Caponero R. Cuidados paliativos. Primeiro Consenso Nacional de Dor Oncológica. 2002:105-112.

De Lima L, Bruera E. The Pan American Health Organization: its structure and role in the development of a palliative care program for Latin America and the Caribbean. J Pain Symptom Manage. 2000;20:440-448.

Soares LGL. Dor em Pacientes com Câncer. Dor. 2003:285-299.

Schoeller MT. Dor Oncológica. Primeiro Consenso Nacional de Dor Oncológica. 2002:13-18.

Bonica JJ, Ventafridda V, Twycross RG. Cancer Pain. The Management of Pain. 1990:400-460.

Prevenção e controle de câncer: normas e recomendações do INCA. Rev Bras Cancer. 2000;48.

Bonica JJ. History of Pain - Concepts and Therapies. The Management of Pain. 1990:2-50.

Hoekstra J, Bindels PJ, van Duijn NP. The symptom monitor. A diary for monitoring physical symptoms for cancer patients in palliative care: feasibility, reliability and compliance. J Pain Symptom Manage. 2004;27:24-35.

Stewart B. Advanced cancer and comorbid conditions: prognosis and treatment. Cancer Control. 1999;6:168-175.

Zeppetella G, O'Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20:87-92.

Soares LG. Methadone for cancer pain: what have we learned from clinical studies?. Am J Hosp Palliat Care. 2005;22:223-227.

Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer pain management. Med J Aust. 2000;173:536-540.

Cuidados Paliativos Oncológicos: Controle de Dor. 2002:15-118.

Levy MH. Pharmacologic treatment for cancer pain. N Engl J Med. 1996;335:1124-1132.

Dickenson AH. NMDA receptor antagonists: interactions with opioids. Acta Anaesthesiol Scand. 1997;41:112-115.

Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain. 1997;70:109-115.

Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain. 1993;52:137-147.

Ettinger DS, Vitale PJ, Trump DL. Important clinical pharmacologic considerations in use of methadone in cancer patients. Cancer Treat Rep. 1979;63:457-459.

De Connor F, Groff L, Brunelli C. Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol. 1996;14:2836-2842.

Sawe J. High-dose morphine and methadone in cancer patients: Clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokinet. 1986;11:87-106.

Gourlay GK, Cherry DA, Cousins MJ. A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patient with cancer. Pain. 1986;25:297-312.

Spiegel P, Campos ASF, Silva MVV. Metadona: titulação e manutenção inicial. Rev Dor. 2003;4:35-41.

Mercadante S, Sapio M, Serretta R. Patient-controlled analgesia with oral methadone in cancer pain: preliminary report. Ann Oncol. 1996;7:613-617.

Mercadante S, Casuccio A, Agnello A. Methadone response in advanced cancer patients with pain followed at home. J Pain Symptom Manage. 1999;18:188-192.

Mercadante S, Casuccio A, Agnello A. Morphine versus methadone in the pain treatment of advanced-cancer patients followed up at home. J Clin Oncol. 1998;16:3656-3661.

Bruera E, Fainsinger R, Moore M. Local toxicity with subcutaneous methadone. Experience of two centers. Pain. 1995;45:141-143.

Bruera E, Watanabe S, Fainsinger RL. Custom-made capsules and suppositories of methadone for patients on high-dose opioids for cancer pain. Pain. 1995;62:141-146.

Shir Y, Shapira SS, Shenkman Z. Continuous epidural methadone treatment for cancer pain. Clin J Pain. 1991;7:339-341.

Walker PW, Klein D, Kasza L. High-dose methadone and ventricular arrhythmias: a report of three cases. Pain. 2003;103:321-324.

Ayonrinde OT, Bridge DT. The rediscovery of methadone for cancer pain management. Med J Aust. 2000;173:536-540.

Doyle D, Hanks GWC, Macdonald N. Oxford Textbook of Palliative Medicine. 1999;11:1283.

Cuidados Paliativos Oncológicos: Controle de Sintomas. 2001:11-61.

De Conno F, Panzeri C, Brunelli C. Palliative care in a national cancer: results in 1987 vs 1993 vs 2000. J Pain Symptom Manage. 2003;25:499-511.

Ross DD, Alexander CS. Management of common symptoms in terminally ill patients: Part I. Fatigue, anorexia, cachexia, nausea and vomiting. Am Fam Physician. 2001;64:807-814.

Mock V. Fatigue management, evidence and guidelines for practice. Cancer. 2001;92(^s6):1699-1707.

Malik UR, Makower DF, Wadler S. Interferon-mediated fatigue. Cancer. 2001;92(^s6):1664-1668.

Winter SM. Terminal nutrition: framing the debate for the withdrawal of nutritional support in terminally ill patients. Am J Med. 2000;109:723-726.

Haughney A. Nausea and vomiting in end-stage cancer. Am J Nurs. 2004;104:40-48.

Ross DD, Alexander CS. Management of common symptoms in terminally ill patients: Part II. Constipation, delirium and dyspnea. Am Fam Physician. 2001;64:1019-1026.

Dean A. The palliative effects of octreotide in cancer patients. Chemotherapy. 2001;47:54-61.

Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage. 2002;24:71-90.

Broder G, Sandoval-Cross C, Berger A. Complications of cancer. Cancer Control. 1999;615:509-516.

Hirst A, Sloan R. Benzodiazepines and related drugs for insomnia in palliative care (Cocharane Review). The Cocharane Library. 2004.

Morita T. Palliative sedation to relieve psycho-existential suffering of terminally ill cancer patients. J Pain Symptom Manage. 2004;28:445-450.

Sykes N, Thorns A. The use of opioids and sedatives at the end of live. Lancet Oncol. 2003;4:312-318.

Jackson KC, Lipman AG. Drug therapy for delirium in terminally ill patients. 2004.

Legrand SB. Dyspnea: the continuing challenge of palliative management. Curr Opin Oncol. 2002;14:394-398.

Edmonds P, Higginson I, Altmann D. Is the presence of dyspnea a risk factor for morbidity in cancer patients?. J Pain Symptom Manage. 2000;19:15-22.

Bruera E, Schmitz B, Pither J. The frequency and correlates of dyspnea in patients with advanced cancer. J Pain Symptom Manage. 2000;19:357-362.

Análise clínica e terapêutica dos pacientes oncológicos atendidos no programa de dor e cuidados paliativos do Hospital Universitário Clementino Fraga Filho no ano de 2003

Clinical and therapeutic analysis of oncology patients treated at the pain and palliative care program of the Hospital Universitário Clementino Fraga Filho in 2003

Giselane Lacerda Figueredo Salamonde; Nubia Verçosa; Louis Barrucand; Antônio Filpi Coimbra da Costa

Resumo

Palavras-chave

Abstract

Keywords

References

Links

Share

Braz J Anesthesiol